AstraZeneca Sets Up Industrial Park In Shanghai
This article was originally published in PharmAsia News
AstraZeneca is planning to increase its investment in China by establishing an AstraZeneca industrial park in Shanghai. It will be a comprehensive center that combines highly efficient management activities, advanced R&D facilities and first-class training amenities. The project, which has started, will be completed by 2010. AstraZeneca's 2007 annual report showed that the company achieved $500 million sales in China (including Hong Kong), an increase of 25 percent over the previous year, even while its global profit decreased by 7.2 percent. (Click here for more - Chinese Language)
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.